MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions
View by Date

Monday, September 23, 2019

1:45pm-3:15pm
MRI based Volumetric analysis of the sub-thalamic and red nuclei in Advanced Parkinson’s disease- an institutional study

V. Shah, R. Alugolu, R. Kandadai, A. Arora (Hyderabad, India)

Neuroanatomy  ·  Les Muses, Level 3
1:45pm-3:15pm
MRI, Clinical, and Neuropathological Findings after Bilateral Intra-striatal Administration of rAAV5-miHTT in Non-human Primates

J. Higgins, B. Blits, L. Spronck, A. Valles-Sanchez, M. Evers, S. van Deventer, P. Konstantinova, M. de Haan (Lexington, MA, USA)

Huntington’s Disease  ·  Agora 3 West, Level 3
1:45pm-3:15pm
Mu opioid receptor agonism, not antagonism, for the treatment of L-DOPA-induced dyskinesia in Parkinson’s disease

E. Bezard, Q. Li, E. Pioli, A. Crossman (Bordeaux, France)

Neuropharmacology  ·  Les Muses Terrace, Level 3
1:45pm-3:15pm
Multi-kinase Abelson (c-Abl) and Discoidin Domain Receptors (DDR1/2) inhibitors, Nilotinib, alters CSF soluble TREM2 (sTREM2) in individuals with Parkinson’s Disease

F. Pagan, M. Hebron, B. Wilmarth, Y. Torres-Yaghi, E. Mundel, N. Yusuf, C. Moussa (Washington, DC, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3
1:45pm-3:15pm
Multimodal characterization of the visual network in Huntington’s disease

O. Odish, S. Gregory, I. Mayer, J.. Mills, E. Johnson, R. Scahill, J. Rothwell, G. Rees, J. Long, S. Tabrizi, R. Roos, M. Orth (Leiden, Netherlands)

Huntington’s Disease  ·  Agora 3 West, Level 3
1:45pm-3:15pm
Muscle Ultrasound Comparison between Early, Intermediate and Late Onset Friedreich’s Ataxia

R. Verbeek, A. Waalkens, M. Kuiper, C. Verschuuren-Bemelmans, J. Vd Hoeven, J. de Vries, J. van Gaalen, M. Willemsen, H. Kremer, K. Bürk, D. Sival (Groningen, Netherlands)

Ataxia  ·  Les Muses, Level 3
1:45pm-3:15pm
MYORG is associated with recessive primary familial brain calcification

D. Arkadir, A. Lossos, D. Rahat, M. Abu Snineh, V. Meiner (Jerusalem, Israel)

Genetics  ·  Les Muses Terrace, Level 3
1:45pm-3:15pm
NBIA-like MRI findings in a patient with Huntington’s disease

T. Shimizu, T. Matsukawa, Y. Abe, H. Suga, N. Tominaga, M. Nagai, T. Iizuka, H. Ishiura, J. Mitsui, S. Tsuji, R. Hanajima, K. Nishiyama (Yonago, Japan)

Huntington’s Disease  ·  Agora 3 West, Level 3
1:45pm-3:15pm
Need of next generation sequencing technology to de-convolute autosomal recessive cerebellar ataxias in India

S. Shakya, R. Kumari, A. Garg, A. Srivastava, M. Faruq (New Delhi, India)

Ataxia  ·  Les Muses, Level 3
1:45pm-3:15pm
Neuritic pathology in Parkinson’s Disease results from loss of anti-oxidant response activity

S. Ryan, M. Stykel, C. Coackley, T. Ryan (Guelph, ON, Canada)

Gene and Cell-Based Therapies  ·  Les Muses Terrace, Level 3
  • «Previous Page
  • 1
  • …
  • 43
  • 44
  • 45
  • 46
  • 47
  • …
  • 75
  • Next Page»

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Striatal Hand Signs” and early diagnosis of Parkinson's Disease: The “Monkey-Wrench Sign”.
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley